

Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs?

Moisés Selman*, Annie Pardo, Naftali Kaminski

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually lethal disease of uncertain etiology [1]. It has been proposed that IPF likely results from an aberrant activation of alveolar epithelial cells after injury that provoke the migration, proliferation, and activation of mesenchymal cells with the formation of fibroblastic/myofibroblastic foci, leading to the exaggerated accumulation of extracellular matrix with the irreversible destruction of the lung parenchyma [2–4]. The molecular mechanisms that determine the persistent nature of IPF are poorly understood. While aberrant activation of developmental pathways that are usually suppressed in adult tissues is often noticed in cancer, it is only rarely observed in non-malignant diseases. In the following pages we present evidence from gene expression studies and animal models of disease that suggest that IPF is characterized by aberrant activation of developmental pathways (Box 1).

Transcriptional Signatures of IPF Lungs Are Enriched with Developmental Genes

Microarray analysis identified an IPF-specific gene expression signature characterized by the up-regulation of genes indicative of an active tissue remodeling program, including extracellular matrix and a large number of myofibroblast/smooth muscle cell-associated and epithelial cell-related genes [3,5]. Recently, we have reanalyzed previously published datasets [3,5,6] using analytical approaches that allow global and unbiased mapping of the functional themes that characterize IPF lungs in comparison to controls or to other interstitial lung disease. The

Research in Translation discusses health interventions in the context of translation from basic to clinical research, or from clinical evidence to practice.

Summary Points

- Idiopathic pulmonary fibrosis is a devastating lung disorder of unknown etiology that inexorably leads to death in a relatively short time because of the lack of any effective therapy.
- IPF lungs are enriched with genes associated with lung development, indicating that embryonic signaling pathways involved in epithelium/mesenchymal communication and epithelial cell plasticity may be aberrantly activated in this disease.
- Developmental genes include members of transcription factor families such as the Sry-related high mobility group–box and forkhead box, and genes related to the Wnt/ β -catenin pathway.
- Epithelial-to-mesenchymal transition, a key process in embryogenesis, may contribute to the fibroblast expansion in IPF lungs. Diverse molecular networks in IPF lungs seem to constitute an environment that drives epithelial cells to express mesenchymal cell properties.
- A better understanding of the dysfunctional activation of embryological pathways in IPF may result in novel, more effective therapeutic strategies.

analyses revealed that IPF lungs were significantly enriched with genes associated with lung development [7]. The up-regulated development-relevant genes included several members of transcription factor families such as the Sry-related high mobility group box and forkhead box, and genes related to the Wnt/ β -catenin pathway [6,7]. (For complete datasets see <http://www.dom.pitt.edu/paccm/Genomics/data.htm>).

While transcription factors active in morphogenesis and differentiation of the embryonic lung may be transiently expressed during adult lung repair, as

in naphthalene injury [8], they are only rarely expressed in the normal lung. In fact, their sustained expression is often thought of as a marker for malignant transformation.

Epithelial Cell Plasticity

Epithelial cells are motile and can migrate away from their nearest neighbors [9]. However, under normal conditions they do not detach and move away from the epithelial layer. This arrangement can be disturbed by a process known as epithelial–mesenchymal transition (EMT). In the process of EMT, epithelial cells lose many of their epithelial characteristics and obtain properties that are

Funding: MS and AP are supported by Universidad Nacional Autónoma de México Grant SDLPTID.05.6; NK is supported by National Institute of Health grants HL073745, HL0793941, HL0894932, and a generous donation by the Simmons family. The funders had no role in the decision to submit the article or in its preparation.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Selman M, Pardo A, Kaminski N (2008) Idiopathic pulmonary fibrosis: Aberrant recapitulation of developmental programs? *PLoS Med* 5(3): e62. doi: 10.1371/journal.pmed.0050062

Copyright: © 2008 Selman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: BMP, bone morphogenetic protein; EMT, epithelial–mesenchymal transition; FAP- α , fibroblast activation protein- α ; IPF, idiopathic pulmonary fibrosis; LEF-1, lymphoid enhancer factor-1; PTEN, phosphatase and tensin homologue deleted on chromosome 10; Shh, Sonic hedgehog; TGF- β , transforming growth factor- β

Moisés Selman is with the Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico. Annie Pardo is with the Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico City, Mexico. Naftali Kaminski is with the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Diseases, Division of Pulmonary and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.

* To whom correspondence should be addressed. E-mail: moiseselman@salud.gob.mx; mselman@yahoo.com.mx

Table 1. Developmental-Associated Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis Compared With Normal Lungs

Gene Bank Accession Number	Gene Name	t-Test p-Value	Fold Change
Wnt pathway			
NM_000474	Twist homolog (Acrocephalosyndactyly) 3; (<i>Drosophila</i>) (TWIST)	4.78E-05	1.93341
NM_003212	Teratocarcinoma-derived growth factor 1 (TDGF1)	0.0107412	1.35966
NM_003012	Secreted frizzled-related protein 1 (SFRP1)	0.000858651	1.12698
AF213459	Ephrin receptor EPHA3	0.00334424	1.09625
AF288571	Lymphoid enhancer factor-1 (LEF-1)	0.00195794	0.677595
NM_004442	EPHB2 (EPHB2), Transcript variant 1	0.00405986	0.644545
NM_003507	Frizzled homolog 7 (<i>Drosophila</i>) (FZD7)	0.0156188	0.60387
NM_007197	Frizzled homolog 10 (<i>Drosophila</i>) (FZD10)	0.0338039	0.52155
NM_133631	Roundabout, axon guidance receptor, homolog 1 (<i>Drosophila</i>) (ROBO1), transcript variant 2	0.00105506	0.480198
NM_003391	Wingless-type MMTV integration site family member 2 (Wnt2)	0.0232113	0.417606
NM_003392	Wingless-type MMTV integration site family member 5A (Wnt5a)	0.0389131	0.403205
NM_004560	Tyrosine kinase-like orphan receptor 2 (ROR2)	0.00834763	0.381742
NM_003506	Frizzled homolog 6 (<i>Drosophila</i>) (FZD6)	0.00884951	0.369912
TGF-beta/BMP			
NM_003239	Transforming growth factor, beta 3	4.68E-07	1.4875
NM_001200	Bone morphogenetic protein-2 (BMP-2)	0.00547695	-1.21824
NM_001202	Bone morphogenetic protein-4 (BMP-4)	0.0148047	1.04239
BC014890	<i>Homo sapiens</i> , SLUG (chicken homolog), zinc finger protein	7.01E-05	0.97068
NM_005900	Mothers against decapentaplegic homolog 1 (<i>Drosophila</i>) (MADH1)	0.00871333	0.803222
X16323	Human hepatocyte growth factor (HGF)	3.32E-05	0.802943
AF288571	Lymphoid enhancer factor-1 (LEF-1)	0.00195794	0.677595
NM_005811	Growth differentiation factor 11 (GDF11)	0.00281541	0.56108
NM_005901	Mothers against decapentaplegic homolog 2 (<i>Drosophila</i>) (MADH2)	0.029944	0.442093
Other developmental-associated genes			
NM_000095	Cartilage oligomeric matrix protein (Pseudochondroplasia, epiphyseal dysplasia 1, multiple)	9.58E-06	2.45674
X57025	Human insulin growth factor I	2.29E-06	2.19103
NM_013999	Mesenchyme homeobox 1 (MEOX1)	0.000279491	1.4691
NM_002632	Placental growth factor, vascular endothelial growth factor-related protein (PGF)	0.000172092	1.2262
NM_000138	Fibrillin 1 (Marfan syndrome) (FBN1)	0.00510626	1.18922
NM_021170	BHLH factor HES4 (LOC57801)	0.0425467	1.10264
NM_018651	Zinc finger protein (ZFP)	1.22E-05	1.06137
NM_005245	Fat tumor suppressor homolog 1 (<i>Drosophila</i>) (FAT)	1.17E-08	1.04874
NM_001999	Fibrillin 2 (Congenital contractural arachnodactyly) (FBN2)	0.0069706	1.03422
NM_014791	Likely ortholog of maternal embryonic leucine zipper kinase (KIAA0175)	0.00256177	0.952044
NM_005733	RAB6 interacting, kinesin-like (RABKINESIN6) (RAB6KIFL)	0.0221156	0.945128
NM_014621	Homeobox D4 (HOXD4)	0.0287928	0.909819
NM_018136	ASPM asp (abnormal spindle) homolog, microcephaly associated (<i>Drosophila</i>) (<i>Homo sapiens</i>)	0.00916607	0.904724
NM_020648	Twisted gastrulation (TSG)	0.00833501	0.851925
NM_016307	Paired related homeobox protein (PRX2)	0.00802912	0.844485
U43148	Human patched homolog (PTC)	8.51E-05	0.836385
NM_013401	RAB3A interacting protein (RABIN3)-like 1 (RAB3IL1)	0.00219661	0.780599
NM_004403	Deafness, autosomal dominant 5 (DFNA5)	0.00651228	0.772185
NM_002333	Low density lipoprotein receptor-related protein 3 (LRP3)	0.0267207	0.737564
NM_003311	Tumor suppressing subtransferable candidate 3 (TSSC3)	0.0373222	0.697632
NM_015507	EGF-like-domain, multiple 6 (EGFL6)	0.01067	0.67935
NM_016574	Dopamine receptor D2 (DRD2), transcript variant 2	0.0205857	0.65134
NM_022843	Protocadherin 20 (PCDH20)	0.0173535	0.644874
NM_005244	Eyes absent homolog 2 (<i>Drosophila</i>) (EYA2)	0.0375536	0.63049
NM_014782	Armadillo repeat protein ALEX2	0.0217291	0.61077

Table 1. Continued

Gene Bank Accession Number	Gene Name	t-Test p-Value	Fold Change
Other developmental-associated genes, continued			
NM_022893	B cell CLL/lymphoma 11A (Zinc finger protein) (BCL11A)	0.0138856	0.608572
NM_000312	Protein C (inactivator of coagulation factors VA and VIIIA) (PROC)	0.0239822	0.604936
NM_018197	Zinc finger protein 64 homolog (Mouse) (ZFP64)	0.00371607	0.553534
NM_005230	ETS-domain protein (SRF accessory protein 2) (ELK3)	0.00955442	0.537755
NM_014071	Nuclear receptor coactivator 6 (NCOA6)	0.00611656	0.484845
NM_004671	Protein inhibitor of activated STAT X (PIASX-BETA)	0.0228299	0.465709
NM_004460	Fibroblast activation protein- α (FAP- α)	0.0486455	0.462095
NM_005776	Cornichon-like (CNIL)	0.00647969	0.429757
NM_004804	WD40 protein CIAO1	0.0115512	0.42985
NM_021008	Suppressin (Nuclear deformed epidermal autoregulatory factor-1 [DEAF-1]-related)	0.00244376	0.418671
NM_016205	Platelet-derived growth factor C (PDGFC)	0.0135145	0.411603
NM_016607	ALEX3 protein (ALEX3)	0.0287724	0.405413
NM_001797	Cadherin 11, type 2 (CDH11), transcript variant 1	0.0220489	0.365774
NM_006246	Protein phosphatase 2, regulatory subunit B (B56), epsilon isoform (PPP2R5E)	0.0322446	0.345418
NM_019035	Protocadherin 18 (PCDH18)	0.0383627	0.325794
NM_003454	Zinc finger protein 200 (ZNF200)	0.0138594	0.296512
NM_003457	Zinc finger protein 207 (ZNF207)	0.0384906	0.280163
NM_005657	Tumor protein P53 binding protein 1 (TP53BP1)	0.0325011	0.279415

From [5–7]. For complete datasets see <http://www.dom.pitt.edu/paccm/Genomics/data.htm>. doi:10.1371/journal.pmed.0050062.t001

distinctive of mesenchymal cells [10]. They become migratory, down-regulate the expression of cell adhesion molecules, primarily E-cadherin, lose their apical–basal polarity, and express mesenchymal molecules such as fibronectin and N-cadherin [11,12]. EMT is a key process in embryogenesis, where it leads to the formation of a migratory mesenchyme that progresses along the primitive streak and populates new areas of the embryo that will develop into mesoderm and endoderm [11].

EMT May Contribute to the Fibroblast Expansion in IPF

An EMT-like process has been reported in cancer progression and metastasis, and in fibrotic disorders [13–23]. Recently, EMT was also observed in lung fibrosis by two groups that noticed numerous cells co-expressing epithelial and mesenchymal markers (thyroid transcription factor-1/ α -smooth muscle actin [24] or surfactant protein C/N-cadherin [25]) within the expanded interstitium in IPF lungs. Moreover, using a triple transgenic mouse reporter system, Kim et al.

demonstrated that EMT plays an important role during lung fibrogenesis and may be more widespread than previously thought [25].


While the mechanisms underlying EMT in IPF are still unclear, many EMT-related genes such as *transforming growth factor (TGF)- β 3* [26,27], *lymphoid enhancer factor-1 (LEF-1)* [28], and *Slug*, a TGF- β target gene required for EMT, as in the developing chicken heart [27], are up-regulated in IPF lungs (Table 1).

Bone Morphogenetic Proteins/ TGF- β Balance and EMT

Bone morphogenetic proteins (BMPs) and TGF- β belong to a superfamily of multifunctional cytokines that includes different isoforms with highly specific functions including wound healing, extracellular matrix remodeling, and the control of epithelial–mesenchymal interactions during embryogenesis [29,30]. Importantly, BMPs antagonize the effects of TGF- β regarding EMT and induce the inverse process of mesenchymal-to-epithelial transition [10]. In tubular epithelial cells, BMP-7 reverses EMT by directly counteracting

TGF- β -induced Smad-dependent cell signaling [31]. In kidney fibrosis, this antagonism may lead to regeneration of injured tissues, suggesting that reversal of EMT may have therapeutic advantages and that fibrosis may be reversible [31]. BMP-2 is decreased and BMP-4 is increased in IPF lungs, compared with controls (Table 1). More importantly, gremlin, the main BMP antagonist that modulates early limb outgrowth and patterning in the mouse embryo [32], is increased in IPF lungs [33]. Gremlin is also found in human diabetic nephropathy, where it colocalizes with TGF- β [34]. TGF- β induces gremlin expression in association with EMT in lung epithelial cells [33]. Taken together, these data suggest that increased TGF- β expression, decreased BMP-2 expression, and active BMP inhibition by gremlin create an EMT-favoring environment in IPF lungs (Figure 1).

The occurrence of EMT in the lung represents a dramatic shift in cellular phenotype and requires reversal of early embryonic programs. Unlike kidney development, where the tubular epithelium originates from



doi: 10.1371/journal.pmed.0050062.g001

Figure 1. Schematic Overview of the Epithelial–Mesenchymal Transition as Modulated by TGF- β and BMPs

In IPF lungs, TGF- β 3, gremlin, and Lef-1 are up-regulated, while BMP-2 is down-regulated. Dysregulation of TGF- β /BMP pathway induces a fibrotic phenotype. EMT, so important in development, is likely to represent one possible response of the alveolar epithelial cell facing sustained injury. Increased expression of BMPs may not only antagonize TGF- β -induced EMT, enhancing re-epithelialization, but also may cause the opposite process, mesenchymal-to-epithelial transition (MET).

cells that undergo mesenchymal-to-epithelial transition [35,36], in the lung the formation of the various cell types lining the proximal and distal airways occurs through the differentiation of the epithelial precursor cells [37]. In other words, it may be more “natural” for kidney epithelial cells to undergo EMT than for lung epithelial cells. In fact, *Snail* activation is sufficient to induce EMT and kidney fibrosis in adult transgenic mice [38]. Thus, EMT in IPF probably represents a dramatic reprogramming of epithelial cells [39].

The Wnt Signaling Pathway

Wnts comprise a large family of secreted glycoproteins that activate multiple distinct types of intracellular signaling pathways through canonical and noncanonical Wnt pathways [40]. Wnt signaling regulates a wide range of developmental processes, and its aberrant activation can lead to disease [41,42]. Canonical Wnt signaling inhibits the phosphorylation and degradation of β -catenin, allowing its translocation into the nucleus and its interaction with the high mobility group domain-containing,

DNA-binding proteins (including the previously mentioned Lef-1) to regulate target gene expression [40–42]. β -catenin influences epithelial cell differentiation in the lung, and is required for the normal differentiation of the bronchiolar and alveolar epithelium [43].

Several Wnt genes are expressed during lung development. Wnt7b-deficient mice exhibit impaired alveolar type I cell differentiation, have hypoplastic lungs, and die at birth of respiratory failure [44]. Similarly, Wnt5a-deficient mice also die shortly after birth from respiratory failure, but in contrast to Wnt7a-deficient mice, they exhibit increased proliferation of lung epithelial and mesenchymal compartments [45,46]. Interestingly, Wnt5a-null embryos showed increased expression of Sonic hedgehog (Shh), suggesting that Wnt5a signaling is required for the normal down-regulation of Shh, and that in the absence of Wnt5a, Shh-induced mesenchymal proliferation continues in late gestation. As will be discussed, epithelial expression of Shh has also been found in IPF lungs [47,48].

The Wnt Signaling Pathway in IPF

Using gene expression microarrays, we demonstrated up-regulation of several members of the Wnt signaling pathway in IPF lungs, compared either with normal lungs or other interstitial lung diseases [3,5] (Table 1). For example, WISP-1 and the secreted frizzled-related protein 2 are increased in IPF compared with hypersensitivity pneumonitis [3]. Several other Wnt pathway-related genes are also overexpressed in IPF lungs compared to normal controls (Table 1; dataset used in [6]; Gene Expression Omnibus database serial accession number GSE2052). The overall balance of the Wnt pathway genes overexpressed in IPF lungs seems to favor activation of the canonic pathway (Figure 2). To date, there is only one study that directly demonstrated aberrant nuclear localization of β -catenin in bronchiolar/alveolar epithelial cells and in fibroblasts from the fibroblastic foci in IPF lungs [49]. Activation of β -catenin in epithelial cells is also indirectly corroborated by the

Five Key Papers in the Field


Armanios et al., 2007 [59] Mutations of genes encoding telomerase reverse transcriptase and telomerase RNA support the idea that pathways leading to telomere shortening are involved in the pathogenesis of familial idiopathic pulmonary fibrosis.

Selman et al., 2006 [3] This was the first paper to compare the gene expression profile of different interstitial lung diseases, providing evidence that idiopathic pulmonary fibrosis is characterized by a distinct transcriptional signature.

Thiery and Sleeman, 2006 [10] In this detailed review on epithelial cell plasticity, the authors dissect the molecular events during which epithelial cells are transformed into mesenchymal cells and vice versa.

Koli et al., 2006 [33] Findings suggest that overexpression of the BMP inhibitor gremlin may play a role in the pathogenesis of IPF, and may function to enhance the fibrotic response by modulating BMP-4 signaling in the lung.

Willis et al., 2005 [24] The authors demonstrate for the first time the epithelial–mesenchymal transition in idiopathic pulmonary fibrosis.



doi: 10.1371/journal.pmed.0050062.g002

Figure 2. Changes in the Expression of Genes Known to be Involved in the Canonical Wnt Pathway

The figure was generated using Ingenuity Pathways Analysis (Ingenuity Systems, <http://www.ingenuity.com/>). Increased genes are in increasing shades of red, decreased are in increasing shades of green. Combined red and green is when different members are changed in different directions.

overexpression of downstream genes such as *MMP-7* and *osteopontin* [5,6], and may also be related to EMT.

Taken together, these data suggest a significant role for the Wnt pathway in IPF.

Fibroblast Expansion in IPF: Mirroring Aggressive Fibromatosis?

A key process in the development of IPF is the formation of the fibroblastic focus. It has been suggested that these foci represent discrete isolated foci of fibroblasts/myofibroblasts. However, using three-dimensional reconstruction of the IPF lungs, other studies have suggested that fibroblast foci are the leading edge of a complex reticulum that is highly interconnected extending from the pleura into the underlying parenchyma [50].

It is increasingly apparent that mesenchymal cells in fibroblastic foci

in IPF exhibit a variety of abnormalities compared to normal lung fibroblasts or fibroblasts from other lung diseases. Some of these abnormalities are related to Wnt pathway signaling or to up-regulation of genes present in exaggerated fibroplasias. β -catenin stabilization (as observed in IPF) has been reported in hyperplastic cutaneous wounds, in keloid scars, and in aggressive fibromatosis, among other disorders [51–53]. Furthermore, transgenic mice that express stabilized β -catenin in mesenchymal cells develop aggressive fibromatosis suggesting a common role for β -catenin in abnormal fibrotic responses [52]. These findings raise the possibility that unchecked activation of a process important in normal wound healing causes abnormal fibroproliferative processes.

Aggressive fibromatosis is a soft tissue tumor composed of a clonal

population of mesenchymal, spindle-shaped cells. It is locally invasive, but rarely metastasizes. Microarray analysis identified four genes uniquely overexpressed in this disorder: *ADAM12*, *WISP-1*, *SOX-11*, and *fibroblast activation protein-alpha (FAP- α)* [54]. *WISP-1* and several members of the *SOX* family are up-regulated in IPF [3]. *FAP- α* is selectively expressed by a subset of fibroblasts in areas of ongoing tissue injury in IPF lungs, but not in normal lung tissue or in tissue with centriacinar emphysema [55]. *FAP- α* is a type II transmembrane serine protease expressed at sites of tissue remodeling in embryonic development [56,57]. *FAP- α* is highly expressed on reactive stromal fibroblasts in over 90% of human epithelial cancers, in healing wounds, and in sarcomas, but is not detected in fibroblasts of benign epithelial tumors or normal adult tissues [57,58].

An additional analogy between IPF and aggressive fibromatosis is the recent evidence that suggests involvement of pathways leading to telomere shortening in the pathogenesis of both disorders [59–61]. Telomeres are noncoding DNA sequences at the end of eukaryotic chromosomes that maintain chromosomal integrity and prevent replication of defective genes [62]. When normal cells reach a critical telomere length, they exit the cell cycle and undergo senescence. The putative relationship between telomerase and human disease is demonstrated in two opposite situations. On one side of the spectrum, most human cancers are characterized by the expression of telomerase, which helps to maintain telomere length and enhance indefinite cell proliferation [63]. On the other side of the spectrum, in pulmonary fibrosis and aggressive fibromatosis, telomerase activity seems to be diminished, with consequent premature telomere shortening. Two recent reports demonstrated that mutations in the genes encoding telomerase components are detected in patients with familial IPF, and occasionally in patients with sporadic IPF [59,60]. According to these studies, pulmonary fibrosis may be at least partially related to a telomerase deficiency and short dysfunctional telomeres, which after DNA damage leads to cell death or cell-cycle arrest.

Box 1. Developmental Pathways Likely Involved in Idiopathic Pulmonary Fibrosis

The Wnt signaling pathway: A signaling pathway that is involved in embryogenesis. Elimination of Wnt causes development of wingless fruit flies, hence the name Wnt (Wingless type). The central player in the signaling cascade of the canonical Wnt pathway is β -catenin. Nuclear β -catenin interacts with transcription factors such as LEF-1/T cell-specific transcription factor to affect transcription. Most Wnts work through specific receptors (Frizzled family of receptors and LRP5/6 co-receptors) and affect degradation and nuclear localization of β -catenin. In adults, dysregulation of the Wnt pathway leads to a variety of abnormalities and degenerative diseases, including cancer and fibrosis.

TGF- β signaling: The TGF- β superfamily of growth factors that includes TGF- β , activins, and BMPs regulates a plethora of biological processes during embryonic development as well as in adult life. A common mechanism through Smad activation applies to signaling mediated by all TGF-beta superfamily members. However, TGF- β ligands signal preferentially through Smad-2 and -3, whereas BMP signaling is mediated through Smad-1, -5, and -8. TGF- β and BMPs have opposite effects in a number of processes. Importantly, TGF- β has a profibrotic effect and induces epithelial-mesenchymal transition, while several BMPs display the contrary effect.

PTEN/PI3 kinase/Akt signaling pathway: The development and function of many tissues that feature tubular networks, including the lung,

are regulated by intricate programs of epithelial cell morphogenesis. PTEN controls epithelial morphogenesis, integrating cellular polarity with tissue architecture. In the adult life, PTEN is an important tumor suppressor, and its dysfunction has been associated with cancer susceptibility. Importantly, PTEN becomes activated during wound healing, promoting fibroblast apoptosis. Decreased PTEN expression is found in IPF fibroblasts, which may enhance their survival, causing active fibroblastic foci persistence.

Hedgehog signaling pathway: A pathway critical in development. The pathway is named after its main ligand hedgehog. Sonic hedgehog is a morphogen that can specify multiple cell identities as a function of its concentration. In the lungs, Shh participates in branching morphogenesis, controlling bud size and shape. Lung-specific overexpression of Shh results in severe increase of interstitial tissue. Strong Shh expression has been identified in reactive alveolar epithelial cells in IPF lungs.

Cross-talk pathways: Emerging evidence supports the theory that the cell response to extrinsic signals relies not only on the effect of a single pathway, but on the integration of numerous signals from a plethora of cross-talking pathways. In this context, TGF- β /Smad, Wnt/ β -catenin, BMP, PTEN, and members of the hedgehog and other families of secreted factors pathways operate through complex interconnections and feedback loops.

Interestingly, cigarette smoking, a strong environmental risk factor for IPF, causes telomere shortening in a dose-dependent manner [64]. Since alveolar epithelial cells play a critical role in the pathogenesis of IPF, and telomerase expression is generally restricted to cells with the capacity to proliferate, it has been speculated that fibrotic response in patients with short telomeres is provoked by a loss of alveolar cells [59], which may be enhanced by exposure to cigarette smoke.

Naturally, there are many differences between aggressive fibromatosis and the fibroblastic foci of IPF, primarily the

clonality of cells; however, some of the pathways that are activated in the former may also participate in the latter.

Phosphatase and Tensin Homologue Deleted on Chromosome 10

Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a phosphatidylinositol phosphate phosphatase that is frequently deleted or inactivated in human cancers [65]. PTEN is critical in development, and PTEN-null embryos die early during embryogenesis [66,67].

Significant to our discussion, a critical role for PTEN in the orchestrated death and removal

of myofibroblasts has been suggested. In response to collagen matrix contraction, PTEN triggers fibroblast apoptosis by leading to decreased PI3 kinase activity and Akt phosphorylation [68]. Myofibroblasts from IPF fibroblastic foci undergo decreased apoptosis compared to myofibroblasts from fibromyxoid lesions of cryptogenic organizing pneumonia, a potentially reversible lung disorder [69,70]. Impaired apoptosis may be at least partially associated with the decreased expression of PTEN observed in IPF lungs [71]. Additionally, since PTEN suppresses fibroblast differentiation to myofibroblasts [71], its reduced expression in IPF fibroblastic foci may have a dual deleterious effect, inducing myofibroblast differentiation and increasing survival.

Importantly, the PTEN/PI3 kinase/Akt signaling pathway is a critical regulator of the interconnection between the TGF- β /Smad, Wnt/ β -catenin, and BMP pathways [72–75].

Sonic Hedgehog

Sonic (Shh), Indian (Ihh), and Desert (Dhh) are the hedgehog family members in mammals. Shh is expressed in the developing lung epithelium, and its primary receptor, Patched-1 (Ptc), is found in mesenchymal cells. In vitro and in vivo studies have shown that Shh increases the proliferation of lung mesenchymal cells, up-regulating the expression of smooth muscle actin and myosin [45].

In developing mice, Shh produced by the epithelium stimulates mesenchymal cell proliferation and differentiation, and importantly, its overexpression causes an aberrant increase in the ratio of interstitial mesenchyme to epithelial tubules [76,77].

In this context, a pattern of strong Shh expression has been identified in reactive alveolar epithelial cells as well as in epithelial cells lining the honeycomb cysts in IPF lungs [47,48], while microarrays indicated up-regulation of its primary receptor (Table 1), suggesting that the Shh pathway is activated on in this disease.

Therapeutic Implications

Identification and targeting of these abnormal mediators/pathways will eventually allow the development of therapeutic agents to control and

Glossary

Aggressive fibromatosis: A disease characterized by the formation of tumors consisting of well-differentiated fibroblasts.

Bone morphogenetic proteins: A family of proteins that were originally described by their ability to cause bone and cartilage formation. Most of them belong to the TGF- β superfamily, and are implicated in various stages of embryonic development.

Epithelial-mesenchymal transition: The process in which an epithelial cell acquires characteristics often attributed to mesenchymal cells. It has been implicated in embryogenesis, cancer, and tissue fibrosis.

Gene expression microarrays: Methods that allow the parallel measurement of the expression of multiple transcripts even of complete genomes, usually by hybridization.

Idiopathic pulmonary fibrosis: A disease characterized by progressive scarring of the lungs, without any recognizable cause.

Myofibroblast: a fibroblast that has muscle cell-like properties such as contractility. These cells are important in wound healing and in fibrosis. In IPF, the cells form collections that are called myofibroblast foci.

Telomerase: An enzyme that adds DNA sequence repeats to the 3' end of DNA in telomeric regions at the end of chromosomes. Telomerase mutations are associated with multiple inherited diseases, while abnormal telomerase activation has been implicated in cancer.

hopefully achieve regression of IPF remodeling. Strategies designed to target the fibrogenic action of TGF- β with agents blocking its signaling pathway, such as the BMP-7, have led to repair of severely damaged renal tubular epithelial cells and to improvement of renal function and survival in mice with nephrotoxic serum nephritis [78]. Along the same line of thought, hepatocyte growth factor, which among other functions inhibits TGF- β -induced EMT, may also be a useful therapeutic approach. It was recently shown that in vivo hepatocyte growth factor gene transfer reduced bleomycin-induced pulmonary fibrosis, improving alveolar epithelial repair,

and importantly, decreasing TGF- β 1 expression [79].

Conclusion

Many pathways that play an essential role during embryological development are inactivated later in life, although some of them may be transiently expressed during adult repair. Aberrant activation of these pathways during adult homeostasis leads to pathological events resulting in cancer, but may also be associated with the development of idiopathic pulmonary fibrosis. Dysfunctional activation of embryological pathways regularly repressed in the adult life may explain the persistent nature of the disease. Although some progress into unraveling the pathogenic mechanisms involved in IPF has been made, many open questions remain, and virtually no effective treatment is currently available. Designing and implementing interventions that target these embryological pathways may be required to develop novel anti-IPF therapies and to significantly improve the outcome of IPF patients. ■

References

1. Gross TJ, Hunninghake GW (2001) Idiopathic pulmonary fibrosis. *N Engl J Med* 345: 517-525.
2. Selman M, King TE, Pardo A (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. *Ann Intern Med* 134: 136-151.
3. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, et al. (2006) Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. *Am J Respir Crit Care Med* 173: 188-198.
4. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ (2004) Mechanisms of pulmonary fibrosis. *Annu Rev Med* 55: 395-417.
5. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, et al. (2002) Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. *Proc Natl Acad Sci U S A* 99: 6292-6297.
6. Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, et al. (2005) Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. *PLoS Med* 2: e251 doi:10.1371/journal.pmed.0020251
7. Studer SM, Kaminski N (2007) Towards systems biology of human pulmonary fibrosis. *Proc Am Thorac Soc* 4: 85-91.
8. Park KS, Wells JM, Zorn AM, Wert SE, Laubach VE, et al. (2006) Transdifferentiation of ciliated cells during repair of the respiratory epithelium. *Am J Respir Cell Mol Biol* 34: 151-157.
9. Schock F, Perrimon N (2002) Molecular mechanisms of epithelial morphogenesis. *Annu Rev Cell Dev Biol* 18: 463-493.
10. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. *Nat Rev Mol Cell Biol* 7: 131-142.
11. Moustakas A, Heldin CH (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. *Cancer Sci* 98: 1512-1520.

12. Zavadil J, Bottinger EP (2005) TGF-beta and epithelial-to-mesenchymal transitions. *Oncogene* 24: 5764-5774.
13. Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. *Curr Opin Cell Biol* 17: 548-558.
14. Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. *Cancer Res* 66: 8319-8326.
15. Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. *J Cell Biol* 172: 973-981.
16. Willis BC, Borok Z (2007) TGF- β -induced EMT: mechanisms and implications for fibrotic lung disease. *Am J Physiol Lung Cell Mol Physiol* 293: L525-L534.
17. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, et al. (2002) Evidence that fibroblasts derive from epithelium during tissue fibrosis. *J Clin Invest* 110: 341-350.
18. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, et al. (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. *Cancer Res* 66: 11271-11278.
19. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, et al. (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. *J Biol Chem* 282: 23337-23347.
20. Alonso SR, Tracey L, Ortiz P, Pérez-Gómez B, Palacios J, et al. (2007) A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. *Cancer Res* 67: 3450-3460.
21. Horikawa T, Yang J, Kondo S, Yoshizaki T, Joab I, et al. (2007) Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. *Cancer Res* 67: 1970-1978.
22. Vasko V, Espinosa AV, Scouten W, He H, Auer H, et al. (2007) Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. *Proc Natl Acad Sci U S A* 104: 2803-2808.
23. Lange-Sperandio B, Trautmann A, Eickelberg O, Jayachandran A, Oberle S, et al. (2007) Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice. *Am J Pathol* 171: 861-871.
24. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, et al. (2005) Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. *Am J Pathol* 166: 1321-1332.
25. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, et al. (2006) Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. *Proc Natl Acad Sci U S A* 103: 13180-13185.
26. Nawshad A, Hay ED (2003) TGFbeta2 signaling activates transcription of the LEF1 gene to induce epithelial mesenchymal transformation during mouse palate development. *J Cell Biol* 163: 1291-1301.
27. Romano LA, Runyan RB (2000) Slug is an essential target of TGFbeta2 signaling in the developing chicken heart. *Dev Biol* 223: 91-102.
28. LaGamba D, Nawshad A, Hay ED (2005) Microarray analysis of gene expression during epithelial-mesenchymal transformation. *Dev Dyn* 234: 132-142.
29. Lin SJ, Lerch TF, Cook RW, Jardetzky TS, Woodruff TK (2006) The structural basis of TGF-beta, bone morphogenetic protein, and

- activin ligand binding. *Reproduction* 132: 179-190.
30. Wahab NA, Mason RM (2006) A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney. *Nephron Exp Nephrol* 104: e129-e134.
 31. Zeisberg M, Shah AA, Kalluri R (2005) Bone morphogenetic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. *Biol Chem* 280: 8094-8100.
 32. Khokha MK, Hsu D, Brunet LJ, Dionne MS, Harland RM (2003) Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. *Nat Genet* 34: 303-307.
 33. Koli K, Myllarniemi M, Vuorinen K, Salmenkivi K, Rynnänen MJ, et al. (2006) Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. *Am J Pathol* 169: 61-71.
 34. Dolan V, Murphy M, Sadlier D, Lappin D, Doran P, et al. (2005) Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. *Am J Kidney Dis* 45: 1034-1039.
 35. Davies JA, Perera AD, Walker CL (1999) Mechanisms of epithelial development and neoplasia in the metanephric kidney. *Int J Dev Biol* 43: 473-478.
 36. Romio L, Fry AM, Winyard PJ, Malcolm S, Woolf AS, et al. (2004) OFD1 is a centrosomal/basal body protein expressed during mesenchymal-epithelial transition in human nephrogenesis. *J Am Soc Nephrol* 15: 2556-2568.
 37. Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, et al. (2000) The molecular basis of lung morphogenesis. *Mech Dev* 92: 55-81.
 38. Boutet A, De Frutos CA, Maxwell PH, Mayol MJ, Romero J, et al. (2006) Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. *EMBO J* 25: 5603-5613.
 39. Selman M, Pardo A (2006). Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. *Proc Am Thorac Soc* 3: 364-372.
 40. Karner C, Wharton KA, Carroll TJ (2006) Apical-basal polarity, Wnt signaling and vertebrate organogenesis. *Semin Cell Dev Biol* 17: 214-222.
 41. Cadigan KM, Liu YI (2006) Wnt signaling: complexity at the surface. *J Cell Sci* 119: 395-402.
 42. Veeman MT, Axelrod JD, Moon RT (2003) A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. *Dev Cell* 5: 367-377.
 43. Mucenski ML, Nation JM, Thitoff AR, Besnard V, Xu Y, et al. (2005) Beta-catenin regulates differentiation of respiratory epithelial cells in vivo. *Am J Physiol Lung Cell Mol Physiol* 289: L971-L979.
 44. Shu W, Jiang YQ, Lu MM, Morrissey EE (2002) Wnt7b regulates mesenchymal proliferation vascular development in the lung. *Development* 129: 4831-4842.
 45. Shannon JM, Hyatt BA (2004) Epithelial-mesenchymal interactions in the developing lung. *Annu Rev Physiol* 66: 625-645.
 46. Li C, Xiao J, Hormi K, Borok Z, Minoo P (2002) Wnt5a participates in distal lung morphogenesis. *Dev Biol* 248: 68-81.
 47. Stewart GA, Hoyne GF, Ahmad SA, Jarman E, Wallace WA, et al. (2003) Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. *J Pathol* 199: 488-495.
 48. Coon DR, Roberts DJ, Loscertales M, Kradin R (2006) Differential epithelial expression of SHH and FOXF1 in usual and nonspecific interstitial pneumonia. *Exp Mol Pathol* 80: 119-123.
 49. Chilosio M, Poletti V, Zamo A, Lestani M, Montagna L, et al. (2003) Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. *Am J Pathol* 162: 1495-1502.
 50. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, et al. (2006) Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. *Am J Respir Crit Care Med* 174: 654-658.
 51. Cheon S, Poon R, Yu C, Khoury M, Shenker R, et al. (2005) Prolonged beta-catenin stabilization and tcf-dependent transcriptional activation in hyperplastic cutaneous wounds. *Lab Invest* 85: 416-425.
 52. Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, et al. (2002) Beta-catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. *Proc Natl Acad Sci U S A* 99: 6973-6978.
 53. Sato M (2006) Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids. *Acta Derm Venereol* 86: 300-307.
 54. Skubitz KM, Skubitz AP (2004) Gene expression in aggressive fibromatosis. *J Lab Clin Med*. 2004; 143: 89-98.
 55. Acharya PS, Zukas A, Chandan V, Katzenstein AL, Pure E (2006) Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. *Hum Pathol* 37: 352-360.
 56. Niedermeyer J, Garin-Chesa P, Kriz M, Hilberg F, Mueller E, et al. (2001) Expression of the fibroblast activation protein during mouse embryo development. *Int J Dev Biol* 45: 445-447.
 57. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, et al. (1999) Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. *J Biol Chem* 274: 36505-36512.
 58. Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, et al. (2005) Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. *J Biol Chem* 280: 19441-19444.
 59. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, et al. (2007) Telomerase mutations in families with idiopathic pulmonary fibrosis. *N Engl J Med* 356: 1317-1326.
 60. Tsakiri KD, Cronkrite JT, Kuan PJ, Xing C, Raghu G, et al. (2007) Adult-onset pulmonary fibrosis caused by mutations in telomerase. *Proc Natl Acad Sci U S A* 104: 7552-7557.
 61. Matsuo T, Hiyama E, Sugita T, Shimose S, Kubo T, et al. (2007) Telomere length and telomerase activity in extra-abdominal desmoid tumors. *Anticancer Res* 27: 411-415.
 62. Phatak P, Burger AM (2007) Telomerase and its potential for therapeutic intervention. *Br J Pharmacol* 152: 1003-1011.
 63. Holt SE, Shay JW, Wright WE (1996) Refining the telomere-telomerase hypothesis of aging and cancer. *Nat Biotechnol* 14: 1734-1741.
 64. Morlá M, Busquets X, Pons J, Sauleda J, MacNee W, et al. (2006) Telomere shortening in smokers with and without COPD. *Eur Respir J* 27: 525-528.
 65. Gericke A, Munson M, Ross AH (2006) Regulation of the PTEN phosphatase. *Gene* 374: 1-9.
 66. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi, PP (1998) Pten is essential for embryonic development and tumour suppression. *Nat Genet* 19: 348-355.
 67. Stiles B, Groszer M, Wang S, Jiao J, Wu H (2004) PTEN less means more. *Dev Biol* 273: 175-184.
 68. Nho RS, Xia H, Diebold D, Kahm J, Kleidon J, et al. (2006) PTEN regulates fibroblast elimination during collagen matrix contraction. *J Biol Chem* 281: 33291-33301.
 69. Thannickal VJ, Horowitz JC (2006) Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. *Proc Am Thorac Soc* 3: 350-356.
 70. Lappi-Blanco E, Soini Y, Paakko P (1999) Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. *Lung* 177: 367-376.
 71. White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, et al. (2006) Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). *Am J Respir Crit Care Med* 173: 112-121.
 72. Hjelmeland AB, Hjelmeland MD, Shi Q, Hart JL, Bigner DD, et al. (2005) Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. *Cancer Res* 65: 11276-11281.
 73. Mahimainathan L, Das F, Venkatesan B, Choudhury GG (2006) Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. *Diabetes* 55: 2115-2125.
 74. Tian Q, He XC, Hood L, Li L (2005) Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. *Cell Cycle* 4: 215-216.
 75. He XC, Zhang J, Tong WG, Tawfik O, Ross J, et al. (2004) BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-b-catenin signaling. *Nat Genet* 36: 1117-1121.
 76. Weaver M, Batts L, Hogan BL (2003) Tissue interactions pattern the mesenchyme of the embryonic mouse lung. *Dev Biol* 258: 169-184.
 77. Bellusci S, Furuta Y, Rush MC, Henderson R, Winnier G, et al. (1997) Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis. *Development* 124: 53-63.
 78. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, et al. (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. *Nat Med* 9: 964-968.
 79. Gazzdar A, Fachinger P, van Leer C, Pierog J, Gugger M, et al. (2007) Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. *Am J Physiol Lung Cell Mol Physiol*; 292: L529-L536.